Search the web
Welcome, Guest
[Sign Out, My Account]

Thursday, March 23 2017 4:19am ET - U.S. Markets open in 5 hours and 11 minutes.
Industry Center - Biotechnology
Industry Center > Biotechnology > Athersys, Inc. Company Profile
More On This Industry
· Summary
· News
· Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Need more? Get unbiased, in-depth information on public and private companies worldwide.
Athersys, Inc. Company Profile
Biotechnology is all the RAGE at Athersys. The development-stage company uses its Random Activation of Gene Expression (RAGE) technology to scan the human genome, identify proteins with specific biological functions, and link those protein functions with gene structures (functional genomics). It is also developing therapies for oncology and vascular applications based on its MultiStem technology, which usesástem cells from adult bone marrow. The firm plans to leverage its technologies by partnering with other biotechs and drugmakers, but it also aims toádevelop its own proprietary drugs. It counts Bristol-Myers Squibb and Angiotech Pharmaceuticals among its partners.
Headlines for Athersys, Inc.
Athersys, Inc. :ATHX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
- Mon Mar 20
6:31 am Athersys announces that clinical investigators have published results from Athersys' Phase 2 trial of MultiStem cell therapy for treating ischemic stroke patients in the peer-reviewed journal The Lancet Neurology
- Mon Mar 20
Two New Publications Highlight the Potential for MultiStem® Treatment of Ischemic Stroke
GlobeNewswire - Mon Mar 20
ATHERSYS, INC / NEW Financials
EDGAR Online Financials - Thu Mar 16
More Headlines...
More on Athersys, Inc.
Quote Financials
Profile Analyst Ratings
Contact Information
Address: 3201 Carnegie Ave
Cleveland, OH 44115-2634
Financial Highlights
Fiscal Year End:December
Revenue (2014):1.60 M
Revenue Growth (1 yr):(-33.40%)
Employees (2014):57
Employee Growth (1 yr):1.80%
Key People
Chief Executive Officer: Susan Young
Chief Operating Officer: Kristin Cortright
Cio: Kevin Mendelsohn
Industry Information
Sector: Healthcare
Industry: Biotechnology
Top Competitors
Curagen Corporation
Osiris Therapeutics, Inc. (osir)

Copyright © 2017 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2017 Morningstar, Inc. All Rights Reserved. Company information © 2017 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2017, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?